Sellas Life Sciences Group Inc (SLS) Stock Price, Quote & News

Company Profile

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is adm...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 200 5278

Website: www.sellaslifesciences.com

Address:

7 Times Square, Suite 2503, New York, United States

TheFrogPrince Dec. 5 at 10:18 PM

$SLS I think about quitting my job every single day.

0 · Reply

sgar9591 Dec. 5 at 10:18 PM

$SLS Another day on the Hebrew stock exchange.

0 · Reply

BioCancerStop Dec. 5 at 10:13 PM

$SLS This is kind of sketchy but has anyone thought of quitting their job to go follow Angelos around such as at this ASH conference just to see who he is speaking with and meeting for dinner etc. Then be able to report back that he in fact is making legitimate connections and with whom and isn't just laying around on the beach scamming shareholders. Kind of seems to me that that would likely validate that there is more going on than we get from the company once in a blue moon. Just to see him sitting in a fine restaurant with ABBV senior execs would be worth it to then load up on Monday morning. Just saying there would be real money in that kind of info and in this case could be well worth the sleuthing.

1 · Reply

RealImbackbears Dec. 5 at 10:08 PM

$SLS i only tell the truth

1 · Reply

Jomppaaz Dec. 5 at 9:58 PM

$SLS Marked this post. See you next week with your "massive drop" 🫡😁

4 · Reply

SLS_IZA_SCAM Dec. 5 at 9:56 PM

$SLS I can't wait for the massive drop at open on Monday when the ASH conference reveals this company is just a scam after they present the same dead data as last year. 😆 🤣 😂 😹 😆 🤣

1 · Reply

GrandmaMoneybaggs Dec. 5 at 9:52 PM

$SLS

0 · Reply

rpc630 Dec. 5 at 9:45 PM

$SLS My BO is set @ 110.00

2 · Reply

TomMac64 Dec. 5 at 9:43 PM

$SLS Good work !

1 · Reply

rpc630 Dec. 5 at 9:42 PM

$SLS I'll stick with Thursday was 80th will be announced PM TUESDAY. Monday PM Pr Ash results. My Prediction FA 12/30 PM. Ash Pr 5.00 80th. 25.00 FA 55.00!!!!

0 · Reply

SELLAS Life Sciences Group, Inc. (SLS) Discusses Innovation in AML Treatments With Focus on GPS and SLS009 Programs Transcript

Oct 27, 2025, 8:30 AM EDT - 5 weeks ago

SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $31 Million in Gross Proceeds

Aug 19, 2025, 9:18 PM EDT - 3 months ago

Sellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026

Aug 7, 2025, 8:30 AM EDT - 4 months ago

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

Jul 7, 2025, 8:45 AM EDT - 5 months ago

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

Jun 5, 2025, 8:45 AM EDT - 6 months ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

Jun 2, 2025, 8:00 AM EDT - 6 months ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 7 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 15, 2025, 8:45 AM EDT - 7 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 13, 2025, 4:05 PM EDT - 7 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 8:45 AM EDT - 7 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

Apr 23, 2025, 10:23 AM EDT - 8 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 8, 2025, 8:45 AM EDT - 8 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

Mar 31, 2025, 3:03 PM EDT - 8 months ago

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst

Mar 20, 2025, 4:05 PM EDT - 9 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 20, 2025, 8:45 AM EST - 10 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

Jan 28, 2025, 3:11 PM EST - 11 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 23, 2025, 8:10 AM EST - 11 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Jan 8, 2025, 8:20 AM EST - 11 months ago

SELLAS Announces Key Business Objectives for 2025

Dec 10, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

Dec 9, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

Nov 27, 2024, 8:45 AM EST - 1 year ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Nov 13, 2024, 4:15 PM EST - 1 year ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 8:00 AM EST - 1 year ago

voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)

Nov 5, 2024, 9:55 AM EST - 1 year ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

Oct 15, 2024, 8:45 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

Oct 10, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Aug 13, 2024, 4:10 PM EDT - 1 year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 6, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Jul 16, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

Jul 8, 2024, 8:45 AM EDT - 1 year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

Jun 24, 2024, 9:05 AM EDT - 1 year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Jun 17, 2024, 9:05 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

Jun 10, 2024, 8:40 AM EDT - 1 year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

May 14, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 1, 2024, 8:35 AM EDT - 1 year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

Apr 29, 2024, 8:45 AM EDT - 1 year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

Apr 19, 2024, 1:49 PM EDT - 1 year ago

Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout

Mar 28, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 26, 2024, 7:35 AM EDT - 1 year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

Mar 19, 2024, 4:05 PM EDT - 1 year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 19, 2024, 8:47 AM EDT - 1 year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

Mar 15, 2024, 9:00 AM EDT - 1 year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Mar 8, 2024, 8:00 AM EST - 1 year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

Mar 1, 2024, 8:30 AM EST - 1 year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

Feb 29, 2024, 8:00 AM EST - 1 year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

Feb 6, 2024, 8:30 AM EST - 1 year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

Jan 25, 2024, 8:45 AM EST - 2 years ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

Jan 9, 2024, 8:30 AM EST - 2 years ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

Jan 4, 2024, 9:01 AM EST - 2 years ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

TheFrogPrince Dec. 5 at 10:18 PM

$SLS I think about quitting my job every single day.

0 · Reply

sgar9591 Dec. 5 at 10:18 PM

$SLS Another day on the Hebrew stock exchange.

0 · Reply

BioCancerStop Dec. 5 at 10:13 PM

1 · Reply

RealImbackbears Dec. 5 at 10:08 PM

$SLS i only tell the truth

1 · Reply

Jomppaaz Dec. 5 at 9:58 PM

$SLS Marked this post. See you next week with your "massive drop" 🫡😁

4 · Reply

SLS_IZA_SCAM Dec. 5 at 9:56 PM

$SLS I can't wait for the massive drop at open on Monday when the ASH conference reveals this company is just a scam after they present the same dead data as last year. 😆 🤣 😂 😹 😆 🤣

1 · Reply

GrandmaMoneybaggs Dec. 5 at 9:52 PM

$SLS

0 · Reply

rpc630 Dec. 5 at 9:45 PM

$SLS My BO is set @ 110.00

2 · Reply

TomMac64 Dec. 5 at 9:43 PM

$SLS Good work !

1 · Reply

rpc630 Dec. 5 at 9:42 PM

$SLS I'll stick with Thursday was 80th will be announced PM TUESDAY. Monday PM Pr Ash results. My Prediction FA 12/30 PM. Ash Pr 5.00 80th. 25.00 FA 55.00!!!!

0 · Reply

thompske Dec. 5 at 9:39 PM

$SLS forget the form 4 data, here is the data for the weekend for all my long brothers and sisters. I ran 3000 simulations using my estimated enrollment timeline, VIALE-A control arm data, ( All treatment naive patients) and data from the GPS ph2 showing 21 mOS. I commented yesterday for REGAL to fail now, we'd have to go up against people that don't have AML. This practically confirms GPS REGAL results will be outstanding. IMO NFA HAGW

8 · Reply

Dmd32 Dec. 5 at 9:37 PM

$SLS happens same time every year

1 · Reply

SLS_IZA_SCAM Dec. 5 at 9:37 PM

$SLS no one was brave enough to sell me PUTS today. You can't be that confident bulls.

1 · Reply

jacksparo Dec. 5 at 9:34 PM

$SLS $LAES $ALT $AKBA $VSTM Not bad not the best but overall holding … Next week might bring some breakthrough.. I am reviewing this week volume and all what happened here!

0 · Reply

Gps_100X_ROI_Potential Dec. 5 at 9:33 PM

$SLS $SMX Very Simple Investment Thesis: SLS Share Price will be much higher - it is Inevitable. - Gps Phase 3 Results are Coming - By the end of Year - BY, as in any day now - Its Dec 8-13 next week. Do not be surprised to see the share price double a couple times while we wait - Positive P3 Results are worth $25B to big Pharma - 100X the Current Short Manipulated $250M puny Market Cap. Do your Due Diligence: Gps will treat upwards of 25,000 AML Remission Patients Each Year. https://www.reddit.com/r/sellasLifescience/

0 · Reply

BMWLTWM3 Dec. 5 at 9:30 PM

$SLS it's not the science, Stooge is the problem and he still could ruin it for everybody..... He doesn't even need to go to Ash in Orlando for a "poster". After 5 years if he doesn't have relationships, contacts to exploit because he is lacking communication with the Bio world like he has with SH, then he is dumber than I believe. This guy is sucking the investors dry, oops with the exception of one, ANSON....how did they do today, stop every potential uptick with sell orders....!! Focus Angelos, get in the IDMC and FDA faces and get these drugs to BP to help "all" patients live longer..... SELL THE COMPANY...!

1 · Reply

rpc630 Dec. 5 at 9:29 PM

$SLS Ceo... "14 fte.... Get it!!!!

1 · Reply

rpc630 Dec. 5 at 9:28 PM

$SLS It's Friday, all the scum is around.

0 · Reply

I_Buy_Stock Dec. 5 at 9:27 PM

$SLS selling stock to pay taxes and buy Xmas presents is not only bullish, it's based. If you thought your financial future was in jeopardy you would buy less presents. Im the one who bought Burns $1.5 sale.

0 · Reply

romaniac05 Dec. 5 at 9:24 PM

$SLS I know there’s speculation of buyout but here’s something I’ve wondered, please give me your input. If the company is seeing such a rise in stock action and they truly believe in the drug they’re creating, not just for profit, isn’t it much more reasonable to assume a partnership? If they have plenty of cash on hand and are making great headway with the control they’re under now, if they really wanted to continue progress would they not continue taking cash and doing their own research? I could see a partnership being very realistic as it allows them to stay in control but give access to more resources, but with their goal why would they choose a buyout? And with their current cash position, they could hold out for some time to find something that is exactly what they’d need. I have a substantial position in this company but just a shower thought

3 · Reply

Longbuy1 Dec. 5 at 9:20 PM

$SLS shorts are scared

0 · Reply

Sellasgps26BAT10 Dec. 5 at 9:20 PM

$SLS Thank you Burns, Stergiou and Cicic for doing this now and getting it out of the way before upcoming Binary News. Now the timing also means Major news is coming out next week.✌️🙏

1 · Reply

Market Cap	197.99M
Revenue (ttm)	0.00
Net Income (ttm)	-30.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	4,107,920
Avg Vol	4,152,820
Day's Range	N/A - N/A
Shares Out	142.44M
Stochastic %K	78%
Beta	2.51
Analysts	Strong Sell
Price Target	$6.83